17,261 trials
Choroidal Neovascularization · Age-Related Maculopathy
Primary: Injection Free Interval — 34; 29 Days
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 28. — -1.1; -0.6 percent change — p=0.0007
Pectus Excavatum
Primary: Affect on Cardiac Activity — 0 participants
Thyroid Cancer
Primary: Objective Response Rate (ORR) — 3 Participants
Prostatic Neoplasms · Metastases, Neoplasm
Primary: Dose Limiting Toxicities (DLTs) — 0; 0; 2 Participants
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression-free Survival at 6 Months — 23 Percentage of participants
Bacterial Infection
Primary: Clinical Response at the Test of Cure (TOC) Visit in the Modified Intent-to-treat (MITT) Population — 84.7; 88.9 percentage of participants
Autism
Primary: Group-specific and Comparison of Change in Aberrant Behavior Checklist-Hyperactivity Subscale Score (Active Omega-3 Group Only, Placebo Group Only and Comparison Between…
Osteoarthritis
Primary: Part A: Number of Participants With Intolerance Events — 0; 0; 0; 0 participants
Head and Neck Cancer
Primary: Response Probability (Confirmed Complete and Partial Responses) — 0; 2; 38 participants
Lymphoma, Non-Hodgkin
Primary: Number of Participants (Par.) With Response as Assessed by the Investigator — 31 participants
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Tumors
Primary: Proportion of Patients Requiring Temporary (>1 Day) or Permanent Withdrawal of AZD2171 Prior to Progression and Within 12 Weeks of First Dose of AZD2171 — 12; 19; 20; 24…
Acute Coronary Syndrome
Primary: Thrombolysis in Myocardial Infarction (TIMI) Clinically Significant Bleeding Events (Primary Safety) — 36; 17; 109; 43 Patients
Prostate Cancer
Primary: Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy. — 26; 26; 13; 4…